Ranbaxy Laboratories Ltd has signed an exclusive licensing agreement with The Debiopharm Group, a Swiss biopharmaceutical development company, to market its 'new chemical entity' (NCE), sanvar (vapreotide acetate).
The injectable molecule will be used for the treatment of acute variceal bleeding and prevention of rebleeding related to portal hypertension. Sanvar can be used in combination with specific treatment such as sclerotherapy or band ligation. Ranbaxy will have exclusive marketing rights in the territories of India, Bangladesh and Nepal.
Sanvar has been granted 'orphan drug' status in the US where it is presently undergoing Phase III clinical trials. Debiopharm expects to file for approval for sanvar in the US in Q1 2007.
Sanvar can be stored at room temperature, an advantage over other products requiring refrigeration, allowing immediate administration, a key benefit in a life-threatening situation.
The agreement will enable Ranbaxy to increase its focus in the gastroenterology this segment.